Sophie Castell: DRD is a game changer and will make a tremendous difference to patients’ quality of life.
Sophie Castell, CEO of Myeloma UK, shared Myeloma UK’s post on X/Twitter:
“DRD is a game changer and will make a tremendous difference to patients’ quality of life. Until we can find a cure for myeloma, it is absolutely crucial that patients are offered the latest, most effective treatments and allowed to live a full life for as long as possible.”
Quoting Myeloma UK’s post:
“We are pleased to share the news that the ground-breaking treatment, daratumumab (Darzalex), lenalidomide (Revlimid) and dexamethasone (DRD) has been approved by the Scottish Medicines Consortium (SMC). This decision means that all patients in Scotland can now access daratumumab at diagnosis. DRD is one of the most effective treatments for newly diagnosed patients who are older, frailer, and ineligible for stem cell transplantation.”
For details click here.
Source: Sophie Castell/Twitter
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023